In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog.
about
Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals.Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8Hepato-preferential insulins: Is this the end, or the end of the beginning?Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action.
P2860
In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog.
@en
In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog.
@nl
type
label
In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog.
@en
In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog.
@nl
prefLabel
In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog.
@en
In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog.
@nl
P2093
P2860
P356
P1476
In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog.
@en
P2093
Andrew Vick
Anja Koester
Chen Zhang
Gordon B Cutler
Hui-Rong Qian
John M Beals
Julie S Moyers
M Dodson Michael
Mark W Farmen
Rebecca A Owens
P2860
P304
P356
10.1124/JPET.115.231035
P407
P50
P577
2016-03-29T00:00:00Z